Orser Capital Management LLC Invests $2.32 Million in Edwards Lifesciences Corporation $EW

Orser Capital Management LLC purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 25,675 shares of the medical research company’s stock, valued at approximately $2,323,000. Edwards Lifesciences makes up approximately 1.2% of Orser Capital Management LLC’s investment portfolio, making the stock its 25th biggest position.

Several other institutional investors also recently modified their holdings of the business. Hanson & Doremus Investment Management purchased a new position in Edwards Lifesciences in the 1st quarter worth about $25,000. JPL Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at about $25,000. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences in the fourth quarter worth approximately $26,000. RMG Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the first quarter worth approximately $26,000. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $27,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Up 0.4%

Shares of EW stock opened at $89.33 on Friday. The company has a current ratio of 4.52, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The stock has a market cap of $51.44 billion, a P/E ratio of 51.34, a P/E/G ratio of 2.23 and a beta of 0.85. The company has a 50 day simple moving average of $88.13 and a two-hundred day simple moving average of $84.04.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter last year, the company posted $0.67 EPS. The company’s revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 620 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $81.14, for a total transaction of $50,306.80. Following the completion of the sale, the vice president owned 40,411 shares of the company’s stock, valued at approximately $3,278,948.54. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 43,539 shares of company stock worth $3,685,364. Corporate insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of research analyst reports. Truist Financial increased their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Mizuho lifted their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $87.00 to $101.00 in a research note on Friday, July 24th. Robert W. Baird increased their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a report on Friday, April 24th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and an average target price of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.